See Gao Yuan with deep knowledge -the seventh prostate cancer summit forum was successfully held

*For medical professionals for reading reference

Big coffee gathers the prostate cancer summit forum, and talks about the latest diagnosis and treatment of prostate cancer.

Prostate cancer is a malignant tumor that is at the forefront of male incidence and mortality. With the improvement of my country's economic level, the improvement of people's living standards, and the extension of the per capita life span, the incidence of prostate cancer in my country is significantly increasing, and it is gradually becoming an important disease that affects the health of men in my country. Prostate cancer continuously updates the technique of cure surgery and precise radiotherapy in cure treatment. At the same time, the diagnosis of images, pathology, and molecular gene diagnosis is also developing rapidly, and it is constantly promoting the standard diagnosis and treatment model of prostate cancer.

On September 17, 2022, the 7th Yangsen China Prostate Cancer Summit Forum was successfully held in the form of "online meeting+live broadcast". Authoritative experts in the urology field at home and abroad gathered, focusing on the diagnosis and treatment of prostate cancer, "knowing deep" in the morning, sharing frontier progress and guideline consensus. Urban doctors brought an academic feast.

First of all, Ms. Zheng Lei, the president of Yang Sen, gave a welcome speech. Welcome and thanks to the experts who attended the seventh prostate cancer summit forum. Yang Sen focuses on the field of prostate cancer therapy, and is committed to bringing the most innovative drugs to more patients at the fastest speed and healthy and well -being of more families.

Figure 1. Ms. Zheng Lei speech

Know deeply

The meeting was served as Professor Huang Jian, Professor Huang Jian, Sun Yixian Memorial Hospital of Sun Yat -sen University, Zhang Xu, General Hospital of the People's Liberation Army, Professor Xing Nianzheng of the Cancer Hospital of the Chinese Academy of Medical Sciences, and Professor Ye Dingwei of Fudan University Cancer Hospital.

In his speech, Professor Huang Jian said: "Through the renewal and preaching of the guide, standardized diagnosis and treatment, and the deepening of medical education, the diagnosis and treatment level of the prostate cancer of urology in my country is constantly improving, and more and more clinical practice has accumulated. Create a diagnosis and treatment model with Chinese characteristics to benefit more patients with prostate cancer. "

Figure 2. Professor Huang Jian conference speech

Academician Zhang Xu delivered a speech and said: "Persist in patients as the center, and colleagues in the field of urinary tumors join hands with Yang Sen Company to make more innovative new drugs quickly and can improve the survival rate of patients and improve the quality of life."

Figure 3. Academician Zhang Xu conference speech

Professor Xing Nianzeng delivered a speech: "Looking forward to researching with the same Taoism, discuss new standards for diagnosis and treatment of prostate cancer, learn new technologies, and find new breakthroughs in prostate cancer treatment."

Figure 4. Professor Xing Nianzheng conference speech

Professor Ye Dingwei delivered a speech: "Explore and promote the MDT innovation diagnosis and treatment model of urinary tumors, and build a one -stop diagnosis and treatment platform with an efficient series, which will help to achieve the most beneficial and most suitable treatment plan for patients."

Figure 5. Professor Ye Dingwei conference speech

See the distance with the prophet

Subsequently, the conference entered the first chapter, "Seeing the Farfare with the Prophet", and Professor Ye Zhangqun of Tongji Hospital affiliated to the Tongji Medical College of Huazhong University of Science and Technology, Professor Xie Liping, the First Affiliated Hospital of Zhejiang University Medical College, and Professor Wang Jianye of Beijing Hospital as the host.

In the same way, Academician Zhang Xu shared the "specialist management of prostate cancer" from four aspects. He said that early screening in China still needs to be further strengthened. Early screening of prostate risk people is an important prerequisite for early intervention; MDT+follow -up), collaborative networks, equipment/technical equipment are the foundation of specialist management; continuous exploration and innovation around clinical practice are the core motivation to optimize the management of specialists; In full coverage, in accumulation and innovation, continuously optimizing patients with patients centered on prostate cancer is the goal.

Figure 6. Academician Zhang Xu share the topic report

Knowing Gao Yuan, Professor Ye Dingwei, a Cancer Hospital Affiliated to Fudan University shared the theme report of "re -define the" PSA Deep Speed ​​"goal, and then improve the high -quality survival of patients with prostate cancer." Professor Ye Dingwei pointed out that prostate special -different antigen (PSA) is a key indicator for patients with metastatic hormone -sensitive prostatal cancer (MHSPC) to achieve the treatment goals. The lower the PSA, the better the patient's prognosis. After the treatment of MHSPC, the patient received the treatment of androgen deprivation (ADT) treatment (ADT) treatment (ADT) The larger the PSA decline, the higher the survival rate of patients. Multiple studies have shown that PSA ≤ 0.2ng/ml is a strong predictive factor for long -term survival benefits of patients with MHSPC; compared to Enzalu amine, etc., Aparel can achieve faster and higher proportion of patients with PSA ≤ 0.2ng/ The response of ML, in terms of improving the overall survival period (OS) and no progressive survival (PFS).

Figure 7. Professor Ye Dingwei shared the theme report

Ascending to the high, Professor Wei Qiang of Huaxi Hospital of Sichuan University interpreted the "2022 Guide Update and New Progress of International Conference". Professor Wei Qiang introduced the 2022 International Guide Renewal Points include the European Urology Society (EAU) Guide (EAU) Guide, the key point of the US comprehensive cancer network (NCCN) guide, and the Canadian Assembly of the Canadian Society of Urology (CUA). Among them, for MHSPC patients, ADT -based combined treatment schemes are more effective than simple ADT; MHSPC preferred tissue specimens for genetic testing; for MHSPC patients, system chemotherapy should be started as soon as possible before clinical symptoms appear.

Figure 8. Professor Wei Qiang share the theme report

Professor of the British Cancer Research Center, Professor Nicholas David James shared the theme report "Current Trends in the Management of Metastatic Hormone Sensitive PRostate Cancer". Based on the voting and thinking of clinical issues in the advanced prostate cancer consensus consensus (APCCC), we share the current management status of international management of MHSPC patients. Rich in content, do not miss. Figure 9. Professor of Nicholas David James shared the theme report

Finally, Professor Zhou Liqun, Professor of the First Hospital of Peking University, Professor Xie Liping and Professor Niu Yuanjie of the Second Hospital of Tianjin Medical University around "how to help patients with prostate cancer under the guidance of" China's health strategy? "

Figure 10. Professor Xie Liping and Professor Niu Yuanjie discussed

See the future with the beginning

The second chapter, "See the Future with the beginning", Professor Qi Lin, Xiangya Hospital of Zhongnan University, Professor Lin Tianyi, Sun Yixian Memorial Hospital of Sun Yat -sen University, Professor Wang Shaogang, Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, and Renji affiliated to Shanghai Jiaotong University Medical College Hospital Professor Xue Wei was chaired by the link.

In order to plan, Professor Zhou Fangjian of the Sun Yat -sen University Tumor Prevention and Control Center brought the theme report of "Achieved Patient -centric MHSPC Management". The incidence of patients with MHSPC is gradually increasing, and patients have the characteristics of initial diagnosis, that is, distant metastasis and higher malignant. Professor Zhou Fangjian pointed out that the domestic and foreign guidelines for the treatment of MHSPC are based on ADT -based combined therapy [especially new endocrine drugs (NHT)]. In the real world, more than half of the American MHSPC patients still choose to treat simply ADT. The proportion of ADT+NHT treatment has shown an upward trend.

Professor Zhou Fangjian said that from the six aspects of screening and diagnosis, treatment selection, efficacy assessment and prognosis, comprehensive treatment of MDT, evaluation and judgment of replacement schemes, sequential therapy and follow -up, and complications of complications, we can manage MHSPC throughout the process. To maximize the benefit of patients while ensuring the quality of the patient's life.

Figure 11. Professor Zhou Fangjian shared the topic report

When the machine was made up, Professor Zou Qing of Jiangsu Cancer Hospital shared the theme report of "MHSPC Starting Treatment Decision". Professor Zou Qing introduced that with the changes in MHSPC treatment, the starting treatment of NHT, MHSPC, OS significantly extended. Apaheamine is currently the only NHT drug that has the indications of the MHSPC throughout the population in China. The starting to treat MHSPC in the starting treatment can make a larger percentage of patients get the in -depth speed of the PSA, significantly extend the survival of patients and guarantee patients who have guaranteed patients. Quality of Life.

Figure 12. Professor Zou Qing shared the theme report

Acquired, Professor Li Gonghui, Affiliated to Zhejiang University Medical College, brought the theme report of "New Endocrine therapy Assistance Period Model Management". Professor Li Gonghui pointed out that there are currently certain limitations of patients with newly -assisted ADT treatment of prostate cancer (LPC). ADT+NHT can significantly improve the PCR of patients, reach the pathological degradation, reduce tumor load without affecting the quality of life and surgical risk of patients. Essence In addition, the results of the existing research show that NHT can significantly extend the PSA-PFS in the auxiliary therapy of LPC, because the benefits of patients with NHT treatment widow metastasis have been significantly benefited, and the guide has been transformed from ADT single drug treatment to ADT-based combined treatment.

Figure 13. Professor Li Gonghui shared the topic report

"I know the matter must be done." Professor Shibenkang, Qilu Hospital of Shandong University shared the theme report, "Aparelide treatment MHSPC research and exploration at the time." Professor Shi Benkang introduced the MHSPC Guide Recommendation and Real World Treatment Model. The 2022 EAU guide strongly recommends early application of NHT treatment MHSPC. Joint treatment based on ADT is the standard treatment of new diagnosis of MHSPC. Real world studies have shown that NHT/DOC treats high tumor load MHSPC, which has a significant benefit of OS compared to ADT/CAB; while NHT has a significant benefit from PFS compared to DOC.

Figure 14. Professor Shi Benkang shared the theme report

See the extensive benefits

The third chapter, "Seeing Guangyi with the Ethics", was chaired by Professor Chen Ming, Professor Chen Ming, Affiliated to Southeast University, and Professor Jin Baiyan, the First Affiliated Hospital of Zhejiang University Medical College.

Figure 15. Professor Chen Ming and Professor Jin Baiye chaired

Be lean to refine, Professor Liu Zhuowei, an affiliated to Cancer Hospital of Sun Yat -sen University, brought the theme report of "advanced urinary epithelial cancer precision treatment". Professor Liu Zhuowei pointed out that the clinical benefits of first -line immunotherapy are limited, and the second -tier immunotherapy is still uncertain. The ADC class needs to pay attention to the adverse reaction of serious or life -threatening. At present, Edicinib is a targeted therapy for new urinary epithelial cancer. PFS has 6 months and OS can reach 1 year.

Figure 16. Professor Liu Zhuowei shared the theme report

Precise casting is efficient and coordinated. Professor Dai Bo, a Cancer Hospital affiliated to Fudan University, shared the theme report of "Joint Treatment of Abbit Dragon as the Corestabel". Professor Dibo said that in Magnitude Studies, BRCA1/2 mutant patients received the Aibi Dragon Union Nichapari treatment well. Treatment is the cornerstone of patients with prostate cancer in the future, and supports further exploration in the future. Figure 17. Professor Dai Bo shared the topic report

Seeing Weizhi, Professor Zeng Hao, Huaxi Hospital of Sichuan University, brought the theme report of "Analysis and Interpretation of the results of prostate cancer gene test results in Chinese patients". Professor Zeng Hao said that the occurrence of prostate cancer is closely related to the transitional pathway of the relevant signal. AR pathways, PI3K pathways, cell cycles, DNA repair, WNT pathways that are common and susceptible to mutation, PI3K pathways, cell cycles, DNA repair, and WNT pathways. Different pathways have a positive or negative effect on patients under different mechanisms, and can actively cope with prostate cancer through target treatment.

Figure 18. Professor Zeng Hao shared the topic report

Professor Wang Jianye, Professor He Zhisong of Peking University First Hospital, Professor Gou Xin, First Affiliated Hospital of Chongqing Medical University, Professor Ho Chuan, Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Professor Guo Jianming, Zhongshan Hospital affiliated to Fudan University, Professor Gao Xu, Shanghai Changhai Hospital, Beijing Professor Gong Kan of the First Hospital of the University, Professor Lu Zhenquan, Shenzhen Hospital of Hong Kong University, Professor Fu Bin, First Affiliated Hospital of Nanchang University, and Professor Dong Baijun, Affiliated to Shanghai Jiaotong University School of Medicine, as the guests' dialogue on the morning meeting. discuss.

See

In the afternoon, the conference began in the opening speech of Professor Ye Dingwei and Professor Zhou Liqun. There were intense and fierce debates, and there were also MDT links and young and middle -aged urinary doctors' innovation points in clinical work.

Figure 19. Professor Ye Dingwei and Professor Zhou Liqun delivered speech opening

See the truth with thoughts

Professor He Dalin, the First Affiliated Hospital of Xi'an Jiaotong University, and Professor Liang Chaochao, the First Affiliated Hospital of Anhui Medical University, presided over the fourth chapter "Seeing the Truth with Thinking".

Professor He Dalin shared "the collision of thoughts and traversal -the consensus thinking of prostate cancer treatment". Professor He Dalin said that most patients in China have a late period of diagnosis, and the five -year survival rate is low, while the "Healthy China 2030" planning outline puts forward the five -year survival rate of the general cancer. In order to achieve the goal, the early prostate cancer should actively observe and reduce the probability of recurrence; for advanced prostate cancer, the time to delay the time of CRPC, improve the quality of life of patients, and achieve the goal of low tumor load MHSPC -close to cure.

Subsequently, the four professors debated the two issues that were controversial in patients with prostate cancer and conducted on -site voting.

Professor Wu Kaijie, Professor Wu Kaijie, Southern Medical University Southern Hospital, and Professor Wu Kaijie, the First Affiliated Hospital of Xi'an Jiaotong University, on the question 1 "Is it necessary to use PSMA PET/CT to clinical M stages with PSMA PET/CT?"

Figure 20. Professor Wu Yan and Professor Wu Kaijie discussed the debate 1

As a necessary recipe, he pointed out that there are still certain limitations in traditional imaging. PSMA PET/CT can early discover the minor metastasis of prostate cancer that cannot be within reach of traditional images and more accurately identify the metastases of patients with prostate cancer. It also helps reduce the number of patient punctures and accurately help the initial diagnosis of the disease.

As a non -necessary party, Professor Wu Kaijie said that there will be some problems with all patients using PSMA PET/CT: patients with low risk still occupy a certain proportion and PSMA PET/CT have not changed the staging of patients with low -risk, and only change the part of the part In the staging of patients with medium -dangerous patients, some patients with high or high -risk prostate cancer are recommended to use PSMA PET/CT for staging. PSMA PET/CT can significantly improve the clinical benefits of patients with high -risk new diagnosis.

Figure 21. On -site voting results of debate 1

Debate 2 "Is it necessary to increase local treatment on the basis of systematic treatment for patients with low tumor load metastatic hormones?"

Figure 22. Professor Li Yonghong and Professor Yu Wei discussed the debate 2

Professor Li Yonghong, as a necessary recipe, said that the systematic treatment of patients with low tumor patients can delay the progress of the disease and increase the benefits of survival. At the same time Based on the use of local treatment.

As a non -necessary prescription, Professor Yu Wei believes that the survival benefits of patients with radiotherapy combined with systems are relatively low. At present, whether MHSPC patients have benefited from local treatment, it is still controversial. The benefit of survival has significantly extended the patient's OS, which helps improve the quality of life of patients, and most experts in APCCC consensus recommend MHSPC patients with simultaneous low tumor load receiving systematic treatment.

Figure 23. Debate 2 On -site voting results

See Heyi

The fifth chapter, "Seeing the Yi Yi Yi Yi Yi", was chaired by Professor Yao Xin of Tianjin Medical University Cancer Hospital and Professor Dong Qiang, Huaxi Hospital of Sichuan University.

Figure 24. Professor Yao Xin and Professor Dong Qiang presided over

Multi -disciplinary case discussion "High tumor load metastatic hormone sensitivity prostate cancer patient treatment option" was by the MDT team of the Xijing Hospital of the Air Force Military Medical University: Professor Qin Guards, Professor Wang Welfare, Professor Wu Peng, Professor Wei Lichun of the Department of Incariasis Professor Zhang Hongmei, Professor Zhang Jing of the Department of Pathology, Professor Ren Jing of the Department of Image, Professor Kang Fei of Nuclear Medicine and Professor Gao Lin of the Department of Dermatology, grasp the timing of tumor -reduced prostate cancer surgery. ; After surgery, the auxiliary treatment method is radiotherapy or saving lymph nodes; the characteristics of prostate mucus adenocarcinoma, PSMA expression, and drug selection; the value of genetic testing and the value of MDT in the value of prostate cancer diagnosis and treatment. Fig

See the gland in innovation

Chapter VI "Seeing the Glanders with Innovation" was chaired by Professor Li Yanjiang, Affiliated Hospital Affiliated Hospital of Qingdao University of Medicine, and Professor Li Yanjiang. Many young and middle -aged experts in the urology field have their own thinking and innovation in clinical work. This conference also chose several aspects to introduce. There are surgical innovation, drug treatment attempts, attempts on adverse reactions, and exploration of precision fields Essence

Figure 26. Professor Tan Wanlong and Professor Li Yanjiang chaired

Professor Pan Jiazheng, an affiliated to Shanghai Jiaotong University School of Medicine, brought the theme report of "DA Vinci peritoneal prostate cancer -improvement HOOD technology" theme report, detailed the advantages of DA Vinci Si robot and HOOD technology in prostate cancer surgery; Professor Yang Chunguang, Affiliated to Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, shared the interim Summary of the Multi -Center Clinical Observation Project of Aparel Antimedia in the Multi -Center Clinical Observation Project. It is found that the 1 -hour plan of Apahamine is safe and feasible. It is very reliable to achieve less patients running legs, early visual results, and avoiding ignition; "Reaction management experience sharing", in order to reduce the incidence of rash and medium -weight rash as much as possible, physical preventive measures can be taken, such as paying attention to sun protection, reducing the frequency of bathing, etc., or pre -treatment of downlink hormones on the doctor's suggestion; finally, "advanced prostate cancer precision accurate accurate prostate cancer precision The theme report of the exploration and practice of treatment and individual chemical treatment was shared by Professor Wang Yong of the Second Hospital of Tianjin Medical University. Professor Wang Yong said that the targeted puncture of the metastases and the original stove enables the MCRPC typing , CRPC relies on molecular types of individualized therapy to make patients more benefit.

Figure 27. Professor Pan Jiayu, Professor Yang Chunguang, Professor Li Jun, and Professor Wang Yong shared the theme report

Professor Xing Jinchun, the First Affiliated Hospital of Xiamen University, Professor Liu Ming of Beijing Hospital, Professor Zhang Ning, Beijing Anzhen Hospital affiliated to the Capital Medical University, Professor Ma Xin, General Hospital of the People's Liberation Army, Professor Zhu Yao, Affiliated to Fudan University, and Wenzhou Medical University affiliated Professor Chen Wei, a hospital, Professor Shouzhong of the Cancer Hospital of the Chinese Academy of Medical Sciences, Professor Xu Danfeng, Affiliated to Shanghai Jiaotong University School of Medicine, Professor Liu Xiuheng of Wuhan University People's Hospital, and Professor Ye Liefu of Fujian Provincial Hospital as the guests of the afternoon conference. Discuss the corresponding theme report.

Conference summary

Professor Ye Dingwei and Professor Zhou Liqun concluded the conference, saying: "See the walk in the afternoon" and echo each other with the morning conference ". The practical session of the middle of China has conducted in -depth discussions. We have a lot of gains and believe that the work of clinicians also has certain guiding significance. Thank you all host, expert speaker and dialogue. At the same time, I would like to thank Yang Sen for hosting the meeting, providing a high -level academic exchange platform for the field experts. "

In the end, Dr. Yu Yu, vice president of Yang Sen's China Medical Affairs Department, thanked and said that defeating cancer and ushered in a better future for patients is our belief that we have been pursuing. In a big role, I would like to thank all experts and scholars to attend the meeting again. I look forward to getting together offline next year.

Figure 28. Dr. Tong Yu thanks

Figure 29. All guests group photos

Scan the two -dimensional code viewing meeting above the meeting ~

*This article is only used to provide scientific information to medical people, and does not represent the viewpoint of this platform

- END -